2013 - 2014 Legislative Priorities
The introduction of biosimilar and interchangeable biologics into clinical practice will present some new challenges that have not historically been present with small molecule generic medicines. Current state rules on substitution will very likely need to be updated or completely re-written in the context of biosimilar and interchangeable biologic medicines. Sound policy in Massachusetts that outlines parameters for safe substitution of interchangeable biologics is the best option to ensure patients have access to high-quality, safe, and effective biologic medicines. MassBio’s core concerns are to safeguard patient safety and the primacy of the physician-patient relationship.
Governor Patrick Signs Bill Granting Patient Access to Interchangeable Biologic Medicines
In June 2014, Massachusetts Governor Deval Patrick signed legislation designed to create a pathway for the substitution of interchangeable biologic medicines in Massachusetts that will ensure both patient access and patient safety. The policies outlined in Chapter 143 align with all five of BIO’s principles on biologic substitution.
MA Biotech Caucus hosts Panel Discussion on Biosimilars September 12, 2013
In September, the Massachusetts Biotech Caucus hosted a panel discussion on “Biosimilars in Massachusetts.” The Massachusetts Legislature is currently considering legislation relative to interchangeable biosimilars, co-sponsored by Representatives Cusack, S. Walsh and Benson.
This event was an opportunity for Massachusetts Legislators and their staff to listen as an expert panel discussed what important factors should be considered when crafting sound policy around biosimilars.
Click here for MassBio's blog post recapping the event.
MassBio and BIO offer testimony in support of interchangeable biosimilars
Robert Coughlin, President and CEO of MassBio, testified at the State House before the Joint Committee on Health Care Financing in favor of legislation that would allow for the substitution of interchangeable biosimilars. MassBio worked with BIO and member companies to develop a set of five principles that should govern the substitution of biologics. The legislation being considered by the Committee aligns with these principles and ensures both patient access and patient safety.
MassBio is a not-for-profit organization committed to advancing the development of critical new science, technology and medicines that benefit people worldwide.
Founded in 1985, MassBio represents over 600 biotechnology companies, academic institutions, research hospitals, and service organizations involved in life sciences and health care, and works to advance policy and promote education, while providing member programs and events, industry information, and services.
- May 22, 2015 Summer Supplier Series: Cambridge Vendor Fair
- May 21, 2015 House Energy and Commerce Committee Unanimously Approves 21st Century Cures
- May 20, 2015 Engage and De-Risk: BioPharm America™ 2015 draws life science dealmaking ecosystem to Boston September 15–17
- May 15, 2015 New Date! MassBio's Annual Walking Tour & Networking Hour
- May 14, 2015 Veolia DOT/RCRA Refresher Class